Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04033627 | TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia | unknown | N/A | 30 | Shanghai Children's Medical CenterOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05543161 | "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | unknown | — | 50 | Sohag UniversityOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04248595 | Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | unknown | Phase 2 | 100 | Ge ZhengOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05512104 | Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression | unknown | — | 51 | Assiut UniversityOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03173612 | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia | unknown | N/A | 132 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05473221 | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05467202 | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467254 | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05463640 | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05404516 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | unknown | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05382390 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | unknown | Phase 3 | 130 | Huihan WangOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05383014 | FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. | unknown | — | 82 | Assiut UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05362942 | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Beijing 302 HospitalOTHER | 0 | May 5, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT05330364 | Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 31 | Ge ZhengOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05053425 | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05042531 | Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia | unknown | N/A | 30 | LanZhou UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05339204 | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission | unknown | N/A | 75 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 21, 2022 | clinicaltrials |
| NCT05333705 | Donor Immune Cell Therapy for Acute Myeloid Leukemia | unknown | Phase 1 | 15 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05249894 | Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy(LAM-SEPSIS) | unknown | — | 400 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | unknown | Phase 1 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04490707 | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | unknown | Phase 3 | 60 | Ge ZhengOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | unknown | Phase 2 | 35 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262465 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML | unknown | N/A | 300 | guomeiOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01752062 | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors(CML1012) | unknown | — | 148 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01761890 | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib(CML1113) | unknown | — | 147 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03751917 | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia(APL0618) | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05152537 | FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia(NTU-CML-001) | unknown | — | 15 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 29, 2022source: clinicaltrials